Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Platinum-Refractory or Resistant Ovarian Cancer
NCT00853307Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2009
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in ovarian carcinoma, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC), sponsored by Millennium Pharmaceuticals. Started Mar 2009; status: completed.
02
Drugs
alisertib
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00853307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00853307.